Table 2 Statistical analysis of clinical features

Sex

1

1

0.98

Male

38

19

14

8

2

6

Female

9

4

2

0

2

1

T stage

0.05

T1-2

5

7

5

0

0.12

0

3

0.3

T3

37

16

7

7

3

4

T4

5

0

4

1

1

0

N stage

0.88

N0

12

7

2

1

0.84

0

3

0.46

N1

10

4

6

2

2

1

N2-3

25

12

8

5

2

3

M stage

M0

47

23

1

16

8

1

4

7

1

TNM Stage

0.27

0.26

0.53

II

14

8

4

0

0

0

III

28

15

7

6

3

4

IVA

5

0

5

2

1

3

Age (year)

67.45 ± 9.01

66.17 ± 8.09

0.27

66.75 ± 8.01

70.75 ± 6.27

0.20

67.25 ± 12.92

67.00 ± 8.00

0.97

BMI (kg/m2)

22.30 ± 3.08

22.94 ± 3.52

0.45

21.12 ± 2.40

22.32 ± 3.36

0.48

25.24 ± 1.99

22.73 ± 3.06

0.92

BSA (m2)

1.6 ± 0.14

1.63 ± 0.18

0.66

1.61 ± 0.14

1.58 ± 0.13

0.44

1.64 ± 0.14

1.65 ± 0.19

0.22

HGB (g/l)

128.28 ± 14.62

126.78 ± 16.56

0.71

121.75 ± 17.43

116.13 ± 22.50

0.43

126.28 ± 22.50

118.29 ± 20.36

0.85

CA72-4 (IU/ml)

4.91 ± 9.45

16.80 ± 39.17

0.29

2.58 ± 2.37

3.06 ± 2.48

0.54

7.53 ± 8.29

21.85 ± 38.32

0.40

CYFRA21-1 (ng/ml)

7.07 ± 6.20

18.80 ± 59.84

0.24

5.49 ± 3.02

5.19 ± 5.04

0.26

4.68 ± 2.02

6.46 ± 4.75

0.71

SCC (ng/ml)

5.25 ± 14.33

2.56 ± 1.52

0.52

4.11 ± 3.94

3.83 ± 3.59

0.95

2.51 ± 0.53

2.18 ± 0.49

0.85

CEA (ng/ml)

2.91 ± 2.56

2.96 ± 1.46

0.25

2.25 ± 0.91

2.69 ± 1.10

0.58

2.77 ± 1.18

3.35 ± 2.60

0.45

CA19-9 (U/ml)

13.01 ± 13.18

12.19 ± 8.67

0.56

29.78 ± 81.64

10.48 ± 7.19

0.93

14.68 ± 8.63

5.24 ± 2.52

0.06

LL(cm)

7.74 ± 2.69

2.76 ± 2.17

0.14

9.13 ± 3.52

7.06 ± 2.76

0.23

7.88 ± 2.60

7.50 ± 3.37

0.57

MDL(cm)

3.76 ± 1.25

2.95 ± 0.86

0.01

4.51 ± 1.10

3.11 ± 1.18

0.02

4.16 ± 0.86

2.61 ± 0.82

0.04